All In Biotech

Drug Trial Radar · NCT07463677

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study Protocol for Evaluating the Efficacy and Safety of Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Mar 15, 2026

Primary completion

May 31, 2028

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigated the efficacy and safety of Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Conditions

  • Lung Cancer (NSCLC)

Interventions

  • Tunlametinib + Cetuximab βDrug

    Study Population: Previously treated subjects with KRAS (non-G12C) mutation-positive, unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) (n=6). Treatment Regimen: Tunlametinib + Cetuximab β Injection Starting Dose Cohort: Tunlametinib: 9 mg per dose, administered orally twice daily (BID). Cetuximab β Injection: 500 mg/m² per dose (calculated based on body surface area), administered intravenously once every two weeks. Cycle Definition: Every 4 weeks constitutes one treatment cycle. Second Dose Cohort: Tunlametinib: 12 mg or 6 mg per dose, administered orally twice daily (BID). Rationale: This cohort aims to identify the optimal dose. From the perspective of maximizing subject benefit, the dose may be either reduced or increased. Therefore, the dose is subject to dynamic adjustment based on ongoing clinical trial observations, rather than following a traditional dose-escalation design. Investigators will continuously review safety data from subjects a

  • Tunlametinib + FulzerasibDrug

    Study Population: Previously treated subjects with KRAS G12C mutation-positive, unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) (n=6). Treatment Regimen: Tunlametinib + Fluorescein Starting Dose Cohort: Tunlametinib: 9 mg per dose, administered orally twice daily (BID). Fluorescein: 600 mg per dose, administered orally twice daily (BID). Cycle Definition: Every 4 weeks constitutes one treatment cycle. Second Dose Cohort: Tunlametinib: 12 mg or 6 mg per dose, administered orally twice daily (BID). Fluorescein: 600 mg per dose, administered orally twice daily (BID). Cycle Definition: Every 4 weeks constitutes one treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: up to 180 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.